Curriculum Vitae

Personal information

Bradley Scott

Work experience

1. Employer: Health Canada
   - Start date: 072022
   - End date: 102022
   - Position: Manager, Clinical Evaluation Division _ Oncology/Hematology
   - Activities: Managing a group of clinical review staff responsible for the review/authorization of products in the area of hematology and hematologic oncology
   - Country: Canada
2. Employer: Health Canada
   - Start date: 062015
   - End date:
   - Position: Senior Clinical Evaluator
   - Activities: Evaluation of clinical evidence to support marketing authorizations of drugs in Canada
   - Country: Canada
3. Employer: Health Canada
   - Start date: 032011
   - End date: 062015
   - Position: Clinical Evaluator
   - Activities: Evaluation of clinical evidence to support marketing authorizations of drugs in Canada
   - Country: Canada
4. Employer: Health Canada
   - Start date: 012009
   - End date: 032011
   - Position: Scientific Evaluator (Biologist)
   - Activities: Evaluation of the risk posed to human health by chemicals found in the environment.
   - Country: Canada

Education and training

1. Subject: University of Ottawa
   - Start date: 012003
   - End date: 032009
   - Qualification: Doctorate in Philosophy
   - Organisation: Cellular and Molecular Medicine Pharmacology Cancer Therapeutics
   - Country: Canada
2. Subject: University of Waterloo
   - Start date: 091997
   - End date: 042002
   - Qualification: Honours Bachelor of Science (Biology)
   - Organisation: Molecular Biology, Microbiology
   - Country: Canada

Additional information

Publications

Arora S, Balasubramaniam S, Zhang W, Zhang L, Sridhara R, Spillman D, Matha JP, Scott B, Golding SJ, Coory M, Pazdur R, Beaver JA. FDA Approval Summary: Pembrolizumab plus lenvatinib for endometrial carcinoma, a collaborative international review under Project Orbis. Clinical Cancer Research, 2020, Oct 1; 26(19):5062 – 5067. Friends of Cancer Research Annual Meeting 2019. November 12, 2019, Washington, DC, USA (Invited Panelist): Keynote Conversation: Project Orbis Real World Evidence Learning Session. November 8, 2019, Ottawa, ON (Invited Speaker): The use of real world evidence to support the review and authorization of Kymriah (tisagenlecleucel) for use in r/rDLBCL Canadian Cancer Research Conference 2019. Nov 3 – 5, Ottawa, ON (Poster and Abstract): Pen, A*, Scott BJ* and Wang J (2019). Health Canada's Regulation of Biosimilar Biologic Drugs for use in Oncology. World Biosimilar Congress 2019. March 3 – 5, 2019, San Diego, CA, USA (Invited Speaker and Panelist): Biosimlars in Canada: State of Clinical and Regulatory Science. Scott BJ and Wang J (2018). Chapter in: Clinical information requirements for biosimlar biologic drug approvals in Canada. In Gutka, Yang and Kakar (Eds.), Biosimilars: Regulatory Clinical and Biopharmaceutical Development (pp. 123 – 144). Springer Nature Switzerland AG, Cham, Switzerland. The Canadian Association for Healthcare Reimbursement, Montreal Day. March 28, 2018, Montreal, QC. (Invited Panelist): Biosimilars in Oncology Session. Canada Talks Pharma 2017. September 11 – 12, Montreal, QC (Invited Speaker): Clinical Considerations for the Authorization of Biosimilars in Canada. Scott BJ. Clinical considerations for the authorization of biosimilar biologic drugs in Canada. Biotech. Focus, Aug/Sep 2017 Ed. Scott BJ, Wang J, Klein AV. Subsequent entry biologic (biosimilar) monoclonal antibodies in Canada: A review of key regulatory issues and lessons learned. Immunome Res,2016 12:2(Suppl):58 Canadian Association for Professionals in Regulatory Affairs, Toronto Dinner Meeting, April 5, 2016 (Invited speaker): Scott BJ. Regulatory Framework for Subsequent Entry Biologics (SEBs) in Canada. III International Congress on Immunopharmacology, Varadero, Cuba, June 15 _ 18, 2015 (Invited speaker): Scott BJ. Subsequent Entry Biologics (Biosimilars) in Canada: A review of key regulatory requirements and lessons learnt. Scott BJ, Klein AV, Wang J. Biosimilar Monoclonal Antibodies: A Canadian Regulatory Perspective on the Assessment of Clinically Relevant Differences and Indication Extrapolation. Journal of Clinical Pharmacology, 2015 Mar; 55(S3):S123_S132. VII Conference of the Pan American Network for Drug Regulatory Harmonization (CPANDRH), Ottawa, Ontario, September 5 – 7, 2013 (Poster and Abstract): Scott

BJ, Klein AV, Wang J. Challenges facing the clinical evaluation and authorization of subsequent entry biologics (SEBs). National Institute for Food and Drug Safety Evaluation (NIFDS – Korea) Biosimilar Workshop, Osong, South Korea, August 29, 30, 2013 (Presentation). Scott BJ. Subsequent Entry Biologics (SEBs): Assay Sensitivity and Indication Extrapolation. Health Canada Science Forum, Ottawa, Ontario, December 3 – 4, 2012 (Poster and Abstract): Scott BJ, Wang J, Klein AV. Identifying challenges facing the clinical evaluation and authorization of Subsequent Entry Biologics (SEBs). Scott BJ, Qutob SS, Liu QY, Ng CE. APM2 is a novel mediator of cisplatin resistance in a variety of cancer cell types regardless of p53 or MMR status. International Journal of Cancer, 2009 Sep; 125(5):1193_204. Scott BJ. APM2 is a novel mediator of cisplatin resistance in a variety of cancer cell types in vitro and in xenograft models of cancer. University of Ottawa Press. Ph.D. thesis defended April 17, 2009. Ng CE, Liu QY, Qutob SS, Scott BJ, Tan WL, Mesak FM. Transcriptomic profiling of radiation_resistant or sensitive human colorectal cancer cells: acute effects of a single X_radiation dose. International Journal of Oncology, 2007, June; 30(6):1369_80. Keystone Symposia: Molecular Targets for Cancer, Whistler, British Columbia, March 2007 (Poster and Abstract): Scott BJ, Ng CE. APM2 is a novel mediator of cisplatin resistance in a variety of cancer cell types.

Projects

Memberships

Memberships Member of the HPFB Accelerated Review Guidance Document working group • Member of the Biologic and Radiopharmaceutical Drugs Directorate dashboarding/planning working group • Member of Health Canada's Biosimilar Biologic Drugs Working Group • Past Member of Health Canada's Toxicogenomics Working Group • Past member of Health/Environment Canada's Azo Benzidine Class Assessment Working Group • Invited peer reviewer for the International Journal of Cancer • Invited peer reviewer for GaBI (Generics and Biosimilars Initiative) Journal Awards • 2021 HPFB Assistant Deputy Minister's Award for Excellence (COVID_19 Vaccines and Treatments) • 2020/2021 Health Canada Awards of Excellence – Innovation and Creativity – Acclerating Access to Cancer Treatments • 2020 BRDD Award for Excellence – Individual Contributions • 2020 HPFB Assistant Deputy Minister's Award for Excellence (Parallel Reviews with FDA and TGA) • 2019 Health Canada Deputy Minister's Award for Excellence (CAR_T cell review team) • 2019 HPFB Assistant Deputy Minister's Award for Excellence (CAR_T cell review team) • 2019 Biologics and Genetic Therapies Directorate Award (3D Bio_printing Working Group) • 2016 Biologics and Genetic Therapies Directorate Award (Biosimilars Working Group) • University of Ottawa, Faculty of Graduate and Post_Doctoral Studies _ Doctoral Research Scholarship (2008)

Other Relevant Information